Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach.

Blum Y, Jaurand MC, De Reyniès A, Jean D.

Mol Cell Oncol. 2019 May 7;6(4):1610322. doi: 10.1080/23723556.2019.1610322. eCollection 2019.

PMID:
31211240
2.

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.

Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D.

Nat Commun. 2019 Mar 22;10(1):1333. doi: 10.1038/s41467-019-09307-6.

3.

Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.

Tranchant R, Quetel L, Montagne F, De Wolf J, Meiller C, De Koning L, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.

Lung Cancer. 2018 Dec;126:15-24. doi: 10.1016/j.lungcan.2018.10.015. Epub 2018 Oct 16.

PMID:
30527180
4.

Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis.

Jean D, Jaurand MC.

Int J Mol Sci. 2018 Jul 27;19(8). pii: E2191. doi: 10.3390/ijms19082191. Review.

5.

[Molecular heterogeneity of malignant pleural mesotheliomas].

Tranchant R, Montagne F, Jaurand MC, Jean D.

Bull Cancer. 2018 Jan;105(1):35-45. doi: 10.1016/j.bulcan.2017.11.007. Epub 2017 Dec 23. Review. French.

PMID:
29277245
6.

Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.

Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.

Clin Cancer Res. 2017 Jun 15;23(12):3191-3202. doi: 10.1158/1078-0432.CCR-16-1971. Epub 2016 Dec 21.

7.

Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.

Andujar P, Lacourt A, Brochard P, Pairon JC, Jaurand MC, Jean D.

J Toxicol Environ Health B Crit Rev. 2016;19(5-6):151-172. Review.

PMID:
27705546
8.

Evaluating the mechanistic evidence and key data gaps in assessing the potential carcinogenicity of carbon nanotubes and nanofibers in humans.

Kuempel ED, Jaurand MC, Møller P, Morimoto Y, Kobayashi N, Pinkerton KE, Sargent LM, Vermeulen RC, Fubini B, Kane AB.

Crit Rev Toxicol. 2017 Jan;47(1):1-58. doi: 10.1080/10408444.2016.1206061. Epub 2016 Aug 18. Review.

9.

Quantification of short and long asbestos fibers to assess asbestos exposure: a review of fiber size toxicity.

Boulanger G, Andujar P, Pairon JC, Billon-Galland MA, Dion C, Dumortier P, Brochard P, Sobaszek A, Bartsch P, Paris C, Jaurand MC.

Environ Health. 2014 Jul 21;13:59. doi: 10.1186/1476-069X-13-59. Review.

10.

[The French mesothelioma network from 1998 to 2013].

Galateau-Sallé F, Gilg Soit Ilg A, Le Stang N, Brochard P, Pairon JC, Astoul P, Frenay C, Blaizot G, Chamming's S, Ducamp S, Rousvoal T, de Quillacq A, Abonnet V, Abdalsamad I, Begueret H, Brambilla E, Capron F, Copin MC, Danel C, de Lajartre AY, Foulet-Roge A, Garbe L, Groussard O, Giusiano S, Hofman V, Lantuejoul S, Piquenot JM, Rouquette I, Sagan C, Thivolet-Bejui F, Vignaud JM, Scherpereel A, Jaurand MC, Jean D, Hainaut P, Chérié-Challine L, Goldberg M, Luce D, Imbernon E.

Ann Pathol. 2014 Feb;34(1):51-63. doi: 10.1016/j.annpat.2014.01.009. Epub 2014 Feb 26. French.

11.

Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.

de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.

Clin Cancer Res. 2014 Mar 1;20(5):1323-34. doi: 10.1158/1078-0432.CCR-13-2429. Epub 2014 Jan 17.

12.

[Pleural lymphatics and pleural diseases related to fibres].

Fleury Feith J, Jaurand MC.

Rev Pneumol Clin. 2013 Dec;69(6):358-62. doi: 10.1016/j.pneumo.2013.09.007. Epub 2013 Nov 5. Review. French.

PMID:
24210155
13.

Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.

Tallet A, Nault JC, Renier A, Hysi I, Galateau-Sallé F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.

Oncogene. 2014 Jul 10;33(28):3748-52. doi: 10.1038/onc.2013.351. Epub 2013 Aug 26.

PMID:
23975423
14.

Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.

Andujar P, Pairon JC, Renier A, Descatha A, Hysi I, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Debrosse D, Galateau-Sallé F, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Validire P, Zucman-Rossi J, Jaurand MC, Jean D.

Mutagenesis. 2013 May;28(3):323-31. doi: 10.1093/mutage/get008. Epub 2013 Feb 22.

PMID:
23435014
15.

Molecular changes in mesothelioma with an impact on prognosis and treatment.

Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC.

Arch Pathol Lab Med. 2012 Mar;136(3):277-93. doi: 10.5858/arpa.2011-0215-RA. Review.

PMID:
22372904
16.

Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Huang SX, Jaurand MC, Kamp DW, Whysner J, Hei TK.

J Toxicol Environ Health B Crit Rev. 2011;14(1-4):179-245. doi: 10.1080/10937404.2011.556051. Review.

17.

Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Jean D, Thomas E, Manié E, Renier A, de Reynies A, Lecomte C, Andujar P, Fleury-Feith J, Galateau-Sallé F, Giovannini M, Zucman-Rossi J, Stern MH, Jaurand MC.

Am J Pathol. 2011 Feb;178(2):881-94. doi: 10.1016/j.ajpath.2010.10.039.

18.

Mesothelioma: Do asbestos and carbon nanotubes pose the same health risk?

Jaurand MC, Renier A, Daubriac J.

Part Fibre Toxicol. 2009 Jun 12;6:16. doi: 10.1186/1743-8977-6-16.

19.

p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.

Andujar P, Wang J, Descatha A, Galateau-Sallé F, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Renier A, Zucman-Rossi J, Pairon JC, Jaurand MC.

Lung Cancer. 2010 Jan;67(1):23-30. doi: 10.1016/j.lungcan.2009.03.018.

20.

Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates.

Daubriac J, Fleury-Feith J, Kheuang L, Galipon J, Saint-Albin A, Renier A, Giovannini M, Galateau-Sallé F, Jaurand MC.

Cell Death Differ. 2009 Aug;16(8):1146-55. doi: 10.1038/cdd.2009.32. Epub 2009 Apr 3.

21.

Eighth international mesothelioma interest group.

Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand MC, Kjaerheim K, Pass HI, Robinson B, Tsao A.

Oncogene. 2007 Oct 25;26(49):6959-67. Epub 2007 May 14.

PMID:
17496929
22.

[How to assess asbestos exposure and identify a population at risk?].

Pairon JC, Jaurand MC, Laurent F, Salmi R, Astoul P, Galateau-Sallé F, Brochard P.

Rev Mal Respir. 2006 Sep;23(4 Pt 3):11S9-27. French. No abstract available.

PMID:
17370376
23.

Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities.

Andujar P, Lecomte C, Renier A, Fleury-Feith J, Kheuang L, Daubriac J, Janin A, Jaurand MC.

Carcinogenesis. 2007 Jul;28(7):1599-605. Epub 2007 Feb 1.

24.

Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.

Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC.

Cell Cycle. 2005 Dec;4(12):1862-9. Epub 2005 Dec 7.

PMID:
16319530
25.

Biomarkers in risk assessment of asbestos exposure.

Bhattacharya K, Dopp E, Kakkar P, Jaffery FN, Schiffmann D, Jaurand MC, Rahman I, Rahman Q.

Mutat Res. 2005 Nov 11;579(1-2):6-21. Epub 2005 Aug 19. Review.

PMID:
16112146
26.

Pathogenesis of malignant pleural mesothelioma.

Jaurand MC, Fleury-Feith J.

Respirology. 2005 Jan;10(1):2-8. Review.

PMID:
15691231
27.

Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines.

Huguenin S, Vacherot F, Fleury-Feith J, Riffaud JP, Chopin DK, Bolla M, Jaurand MC.

Cancer Lett. 2005 Feb 10;218(2):163-70.

PMID:
15670893
28.

Mesothelioma pathogenesis, facts and expectations.

Jaurand MC.

Pathol Biol (Paris). 2005 Feb;53(1):41-4. Review.

PMID:
15620609
29.

Lectin-based three-color flow cytometric approach for studying cell surface glycosylation changes that occur during apoptosis.

Batisse C, Marquet J, Greffard A, Fleury-Feith J, Jaurand MC, Pilatte Y.

Cytometry A. 2004 Dec;62(2):81-8.

30.

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

Wallerand H, Bakkar AA, de Medina SG, Pairon JC, Yang YC, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian JC, Jaurand MC, Zhang ZF, Radvanyi F, Thiery JP, Chopin DK.

Carcinogenesis. 2005 Jan;26(1):177-84. Epub 2004 Sep 3.

PMID:
15347601
31.

Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines.

Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP, Chopin DK, Vacherot F.

Prostate. 2004 Oct 1;61(2):132-41.

PMID:
15305336
32.

Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment.

Kettunen E, Vivo C, Gattacceca F, Knuutila S, Jaurand MC.

Cancer Genet Cytogenet. 2004 Jul 1;152(1):42-51.

PMID:
15193440
33.

Growth, differentiation and senescence of normal human urothelium in an organ-like culture.

Daher A, de Boer WI, Le Frère-Belda MA, Kheuang L, Abbou CC, Radvanyi F, Jaurand MC, Thiery JP, Gil Diez de Medina S, Chopin DK.

Eur Urol. 2004 Jun;45(6):799-805.

PMID:
15149756
34.

Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines.

Huguenin S, Vacherot F, Kheuang L, Fleury-Feith J, Jaurand MC, Bolla M, Riffaud JP, Chopin DK.

Mol Cancer Ther. 2004 Mar;3(3):291-8.

35.

[Viruses and human oncogenesis].

Jaurand MC, Fléjou JF.

Ann Pathol. 2003 Nov;Spec No 1:S76-82. French. No abstract available.

PMID:
14997619
36.

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.

Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG.

Cancer Res. 2003 Dec 1;63(23):8108-12.

37.

[SV40 and cancer: a recurring debate].

Jaurand MC.

Med Sci (Paris). 2003 Jan;19(1):5-7. French. No abstract available.

38.

Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours.

Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, Levy F, Janin A, Giovannini M, Jaurand MC.

Oncogene. 2003 Jun 12;22(24):3799-805.

PMID:
12802287
39.

Transfer into a mesothelioma cell line of tumor suppressor gene p16 by cholesterol-based cationic lipids.

Piperno-Neumann S, Oudar O, Reynier P, Briane D, Cao A, Jaurand MC, Naejus R, Kraemer M, Breau JL, Taillandier E.

Biochim Biophys Acta. 2003 Apr 1;1611(1-2):131-9.

40.

Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation.

Vivo C, Lecomte C, Levy F, Leroy K, Kirova Y, Renier A, Kheuang L, Piedbois P, Chopin D, Jaurand MC.

Br J Cancer. 2003 Feb 10;88(3):388-95.

41.

Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma.

Gattacceca F, Pilatte Y, Billard C, Monnet I, Moritz S, Le Carrou J, Eloit M, Jaurand MC.

Clin Cancer Res. 2002 Oct;8(10):3298-304.

42.

Control of cell cycle progression in human mesothelioma cells treated with gamma interferon.

Vivo C, Lévy F, Pilatte Y, Fleury-Feith J, Chrétien P, Monnet I, Kheuang L, Jaurand MC.

Oncogene. 2001 Mar 1;20(9):1085-93.

43.

Absence of SV40 large T-antigen expression in human mesothelioma cell lines.

Pilatte Y, Vivo C, Renier A, Kheuang L, Greffard A, Jaurand MC.

Am J Respir Cell Mol Biol. 2000 Dec;23(6):788-93.

PMID:
11104732
44.
45.

DNA breakage in asbestos-treated normal and transformed (TSV40) rat pleural mesothelial cells.

Levresse V, Renier A, Levy F, Broaddus VC, Jaurand M.

Mutagenesis. 2000 May;15(3):239-44.

PMID:
10792017
46.

Investigations of DNA Damage Produced by Asbestos Fibers in Rat Pleural Mesothelial Cells.

Jaurand MC.

Inhal Toxicol. 2000 Jan;12 Suppl 3:183-7. doi: 10.1080/08958378.2000.11463212.

PMID:
26368615
47.

Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells.

Le Pimpec-Barthes F, Bernard I, Abd Alsamad I, Renier A, Kheuang L, Fleury-Feith J, Devauchelle P, Quintin Colonna F, Riquet M, Jaurand MC.

Br J Cancer. 1999 Dec;81(8):1344-50.

48.

Changes in expression and microheterogeneity of the genetic variants of human alpha1-acid glycoprotein in malignant mesothelioma.

Hervé F, Duché JC, Jaurand MC.

J Chromatogr B Biomed Sci Appl. 1998 Sep 11;715(1):111-23.

PMID:
9792503
49.

Detection of SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma and other pulmonary diseases.

Galateau-Salle F, Bidet P, Iwatsubo Y, Gennetay E, Renier A, Letourneux M, Pairon JC, Moritz S, Brochard P, Jaurand MC, Freymuth F.

Dev Biol Stand. 1998;94:147-52. Review.

PMID:
9776236
50.

Non-animal Tests for Evaluating the Toxicity of Solid Xenobiotics.

Fubini B, Aust AE, Bolton RE, Borm PJ, Bruch J, Ciapetti G, Donaldson K, Elias Z, Gold J, Jaurand MC, Kane AB, Lison D, Muhle H.

Altern Lab Anim. 1998 Sep-Oct;26(5):579-617. No abstract available.

PMID:
26042488

Supplemental Content

Loading ...
Support Center